The Australian/Stockhead: Cynata featured in analysis of key 2026 biotech trial readouts

Tim Boreham's latest Biocurious column examines ASX biotech companies approaching pivotal trial results in 2026, highlighting Cynata's dual clinical catalysts this quarter. Writing in The Australian and Stockhead, Boreham notes: "Cynata Therapeutics (ASX:CYP) offers a double delight: readouts in the current quarter from a phase III knee osteoarthritis (OA) study and also a phase II adult acute graft-versus-host disease (GvHD) trial." The article observes that expectations are running high given Mesoblast's breakthrough FDA approval for paediatric GvHD stem-cell treatment, and explains how Cynata's Cymerus™ platform addresses the challenge of creating consistent and scalable therapies: "Cynata's Cymerus platform creates a renewable mesenchymal stem cell supply, from a single donation that does not need to be repeated."

Boreham notes the Phase 3 Sculptor trial enrolled 320 patients, while the Phase 2 aGvHD trial completed its 100-day primary evaluation period in late March with 65 participants across Australia, US, and Europe. The column provides broader context on the significance of late-stage trial results for the biotech sector.

Read: https://tinyurl.com/ycwvr4f8